Moderna says its COVID-19 vaccine is safe and effective in 12- to 17-year-olds

Moderna Says Its COVID-19 Vaccine Is, Safe and Effective, in 12- to 17-Year-Olds.On Tuesday, Moderna announced the results of itsPhase 2 trial of the administration of its COVID-19vaccine to children ages 12 to 17. .According to results involving 3,732 childrenin the United States, their vaccine produces animmune response to COVID-19.That immune response was found to be equivalentto the immune response produced in adults. .Moderna’s results in the children were “consistentwith a vaccine efficacy of 100%.”.The vaccine was found to be 93% effective atpreventing mild cases of COVID-19 after one dose. .These mild cases only involved one symptomof COVID-19, rather than two or more. .No significant safety concerns were identified:only mild side effects after the second dose such as headache,fatigue, muscle pain, pain at the injection site and chills.Moderna plans to submit its findingsand a request for authorization to the U.S. Foodand Drug Administration in early June. .Currently, Pfizer’s COVID-19 vaccine is the onlyone to have gained emergency use authorizationfrom the FDA to include 12- to 15-year-olds